



PAUL COHEN'S *Marijuana Hub*

A Division of Cohen Grassroots Research, Inc. www.cohengrassroots.com



Newsletter: July 21, 2015, Issue #169 -- www.cohenresearch.com

Cohen Grassroots Research, Inc. is the Nation's Number #1 Micro Cap and Cannabis Research Firm
IR Research Reports (1,000+) - Distribution to 100s of thousands of investors

HOW TO MAKE MONEY IN THE MARIJUANA STOCK MARKET

WHAT CANNABIS SCIENCE, INC. CBIS DOES

On July 17, 2015 Alan Brochstein stated that: "CBIS has been burning investors for over six years, yet it has the audacity to say that it has "prepared the blueprint for establishing basic science exploration and explanation for medicinal benefits associated with cannabinoid products." What has it been doing for the past six years???"

Cannabis Science, Inc., OTC QB: CBIS takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years. Currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of illnesses caused by infections, as well as for age-related illness. Cannabis Science's initial focus is development of research on HIV, skin cancers and neurological conditions.

The Cannabis Science model is similar to a drug development company by creating a cannabinoid portfolio of intellectual property and other trade secrets. To support this research and development portfolio, Cannabis Science is working on creating cannabis-based, cannabinoid medical applications and research for drug development that one day may reach multi-billion dollar markets. The Company is working on designing formulations for possible future treatments for skin cancers. In another area of development, the Company believes cannabinoids can successfully treat drug resistant strains of Kaposi's Sarcoma, a condition presented in many long-term HIV patients. Cannabis Science has plans to formulate a novel approach to directly treat the HIV virus that may have benefits and applications for other infectious diseases. The Company has a need for the continuation of financing, and is actively seeking collaborations with partners to share complimenting models, which can be vertically integrated in research, development and ultimately commercialization.

CBIS has indeed established a new and remarkable research blueprint that Brochstein has not inquired about, nor does he understand its profound effect. A microbiologist or biochemist would understand the blueprint. Alan Brochstein is neither.